Image Place holder

Kendra Sweet, MD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Focus: Leukemia , MDS, Myelodysplastic Syndromes (MDS)

Dr. Sweet's clinical interests include myeloid malignancies with a particular focus on acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). She completed her medical education at the Medical College of Virginia – Virginia Commonwealth University. Her Internal Medicine residency was completed at the University of Arizona, and her Hematology and Medical Oncology fellowship training was done at Moffitt Cancer Center/The University of South Florida. She is currently an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center and has an appointment as an Assistant Professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine.

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • H. Lee Moffitt Cancer Center and Research Institute - Hematology-Oncology

Residency:

  • University of Arizona - Internal Medicine

Medical School:

  • Virginia Commonwealth University School of Medicine - MD
Participating Trials

CLINICAL TRIAL 19456
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Condition: Malignant Hematology
Intervention: CP-868596 (Crenolanib); Crenolanib (); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); Midostaurin (); daunorubicin ()
Open

CLINICAL TRIAL 19737
S1712, " A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease.- Study Chairs: Kendra Sweet, M.D., Jerald P. Radich, M.D.
Condition: Malignant Hematology
Intervention: AMN107 (Nilotinib); Dasatinib (BMS-354825); Jakafi (Ruxolitinib); Nilotinib (); Ruxolitinib (); Tasigna (Nilotinib)
Open

CLINICAL TRIAL 19870
A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Condition: Malignant Hematology
Intervention: IMGN632 ()
Open

CLINICAL TRIAL 19660
Treatment Free Remission After Combination Therapy with Ruxolitinib Plus Tyrosine Kinase Inhibitors in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Condition: Malignant Hematology
Intervention: AMN107 (Nilotinib); Dasatinib (BMS-354825); Gleevac (Imatinib Mesylate); Imatinib Mesylate (); Nilotinib (); Ponatinib (AP24534); Rituxan (rituximab); STI571 (Imatinib Mesylate); Tasigna (Nilotinib); rituximab ()
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L. Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC). Leuk Res. 2019 Sep;84:106194. Pubmedid: 31357093.
  • Jim HSL, Hyland KA, Nelson AM, Pinilla-Ibarz J, Sweet K, Gielissen M, Bulls H, Hoogland AI, Jacobsen PB, Knoop H. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial. Cancer. 2019 Sep.126(1):174-180. Pubmedid: 31553815.
  • Sweet K, Komrokji RS, Padron E, Cubitt CL, Turner JG, Zhou J, List AF, Sallman DA, Dawson JL, Sullivan DM, Chavez J, Shah BD, Lancet JE. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2019 Oct. Pubmedid: 31636097.
  • Talati C, Dhulipala VC, Extermann M, Al Ali N, Kim J, Komrokji R, Sweet K, Kuykendall A, Sehovic M, Reljic T, Djulbegovic B, Lancet JE. Comparisons of commonly used frontline regimens on survival outcomes in patients age 70 years and older with acute myeloid leukemia. Haematologica. 2019 May. Pubmedid: 31073071.
  • Chan O, Talati C, Sweet K, Pinilla-Ibarz J. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?. Expert Rev Hematol. 2019 Mar.12(4):225-233. Pubmedid: 30855193.
  • Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE. A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS). Leuk Res. 2019 Jun.81:56-61. Pubmedid: 31030089.
  • Andrew K, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients. Am J Hematol. 2019 Jan.94(1):87-92. Pubmedid: 30390311.
  • de Haas V, Ismaila N, Advani A, Arber DA, Dabney RS, Patel-Donelly D, Kitlas E, Pieters R, Pui CH, Sweet K, Zhang L. Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. J Clin Oncol. 2019 Jan.37(3):239-253. Pubmedid: 30523709. Pmcid: PMC6338392.
  • Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS. Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis. Am J Hematol. 2019 Aug.94(12):E314-E317. Pubmedid: 31444809.
  • Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr;380(17):1628-1637. Pubmedid: 31018069.
  • Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2018 Sep;16(9):1108-1135. Pubmedid: 30181422.
  • Talati C, Sweet K. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape. Leuk Res. 2018 Oct;73:58-66. Pubmedid: 30223250.
  • Talati C, Sweet KL. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. Int J Hematol Oncol. 2018 Oct.7(3):IJH04. Pubmedid: 30405902. Pmcid: PMC6219429.
  • Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F, Hyland K, Nelson A, Pinilla-Ibarz J. A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leuk Res. 2018 Nov;74:89-96. Pubmedid: 30340199.
  • Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation. Ann Hematol. 2018 Mar;97(3):435-441. Pubmedid: 29189896.
  • Sweet K, Lancet J. State of the Art Update and Next Questions: Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):703-709. Pubmedid: 29110833.
  • Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience. Am J Hematol. 2017 Mar;92(3):232-237. Pubmedid: 28006850.
  • Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. Pubmedid: 28869184.
  • Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. Pubmedid: 29030092.
  • Sweet K, Pinilla-Ibarz J. NCCN and ELN: What do the guidelines tell us?. Best Pract Res Clin Haematol. 2016 Sep;29(3):264-270. Pubmedid: 27839567.
  • Sweet K, Pinilla-Ibarz J. Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question. Crit Rev Oncol Hematol. 2016 Jul;103:99-108. Pubmedid: 27262540.
  • Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hagelstrom RT, Hobbs G, Jagasia M, Kantarjian HM, Kropf P, Metheny L, Moore JO, Ontiveros E, Purev E, Quiery A, Reddy VV, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Tibes R, Yang DT, Gregory K, Sundar H, Deininger M, Radich JP. NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Ne. 2016 Dec;14(12):1505-1512. Pubmedid: 27956535.
  • Pinilla-Ibarz J, Sweet KL, Corrales-Yepez GM, Komrokji RS. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned. Onco Targets Ther. 2016 Aug;9:4937-4957. Pubmedid: 27570458. Pmcid: PMC4986686.
  • Pinilla-Ibarz J, Sweet K, Emole J, Fradley M. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. Anticancer Res. 2015 Dec;35(12):6355-6364. Pubmedid: 26637844.
  • Sweet K, Lancet JE. Novel therapeutics in acute myeloid leukemia. Curr Hematol Malig Rep. 2014 Jun;9(2):109-117. Pubmedid: 24633743.
  • Sweet K, Pinilla-Ibarz J, Zhang L. Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations. Patient Prefer Adherence. 2014 Jul;8:981-986. Pubmedid: 25045255. Pmcid: PMC4099191.
  • Sweet K, Al Ali NH, Dalia SM, Komrokji RS, Crescentini RM, Tinsley S, Lancet JE, Papenhausen PR, Zhang L, Pinilla-Ibarz J. Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec;100(6):567-574. Pubmedid: 25281405.
  • Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013 Jul;6:54. Pubmedid: 23870290. Pmcid: PMC3737033.
  • Sweet KL, Hazlehurst LA, Pinilla-Ibarz J. The one-two punch: combination treatment in chronic myeloid leukemia. Crit Rev Oncol Hematol. 2013 Dec;88(3):667-679. Pubmedid: 23969231.
  • Sweet K, Oehler V. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?. Hematology Am Soc Hematol Educ Program. 2013 Dec;2013:184-188. Pubmedid: 24319180.
  • Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer. 2013 Apr;21(4):1097-1103. Pubmedid: 23179489.